MS. BRIEANA L SMITH MSN, APRN, CNP-PC
Prescription History 1104497239
Nurse Practitioner - Pediatrics in Solon, OH

NPI Status: Active since July 09, 2021

Contact Information

34055 SOLON RD STE 200
SOLON, OH
ZIP 44139
Phone: (440) 914-7840

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MS. BRIEANA L SMITH MSN, APRN, CNP-PC, an active Pediatrics specialist practicing in Solon, OH. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 34 documented patient claims. Among these therapy options, the most frequently utilized medication is Phenobarbital, which accounts for 23 claims alone.

Medication Index

No matching medications currently found on file.

Diazepam

Generic Formulation: DiazepamSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 272
OH State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills31.4
Peer Average Days Supply776
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.1% less volume than the regional standard for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $641.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$58.29

State Avg Cost Per Claim

$8.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.

Therapeutic Applications

This medication is used to treat episodes of increased seizures (such as cluster or breakthrough seizures) in people who are already taking medications to control their seizures. This product is only recommended for short-term treatment of seizure attacks. It is not for ongoing daily use to prevent seizures. Uncontrolled seizures can turn into serious (possibly fatal) seizures that do not stop (status epilepticus). This medication is not recommended for children younger than 6 months of age because of the risk of serious side effects. Diazepam works by calming the brain and nerves. It belongs to a class of drugs known as benzodiazepines.

Phenobarbital

Generic Formulation: PhenobarbitalSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 690
OH State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills28.9
Peer Average Days Supply762
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $989.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.02

State Avg Cost Per Claim

$37.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

Therapeutic Applications

This medication is used alone or with other medications to control seizures. Controlling and reducing seizures lets you do more of your normal daily activities, reduces your risk of harm when you lose consciousness, and lessens your risk for a possibly life-threatening condition of frequent, repeated seizures. Phenobarbital belongs to a class of drugs known as barbiturate anticonvulsants/hypnotics. It works by controlling the abnormal electrical activity in the brain that occurs during a seizure. This medication is also used for a short time (usually no more than 2 weeks) to help calm you or help you sleep during periods of anxiety. It works by affecting certain parts of the brain to cause calming.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MS. BRIEANA L SMITH MSN, APRN, CNP-PC provides transparency into local medical care patterns within Solon, OH.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pediatrics** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.